HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 01/29/2013 -- Keryx Biopharmaceuticals’ (NASDAQ:KERX): It has been a volatile year for Keryx Biopharmaceuticals: The stock had fallen from $5.00 to $1.50 early in 2012 after top-line data for its drug Perifosine did not meet expectations. However, on Monday the stock is higher by more than 40% after announcing that its other drug, Zerenex, a kidney disease drug, met its late-stage trial goal with the FDA. The company is now seeking a marketing authorization with the EMA and is expected to submit a new drug application to the FDA later this year.
Receive A Free Trend Analysis Report On KERX Here.
Furiex Pharmaceuticals (NASDAQ:FURX) gets a big approval, Shares of Furiex Pharmaceuticals rallied almost 50% after clearance from the FDA for a substance, alogliptin, and two combinations that aid in the treatment of Type 2 diabetes. Furiex has partnered with Takeda Pharmaceuticals, and now that the approval has occurred, Furiex is eligible to receive a milestone payment of $25 million. Furiex is also poised to receive royalties and sales-based milestone payments. Most expect the drug to benefit from a large patient population of Type 2 diabetes, and could lead to over $1 billion in total sales. Therefore, Furiex with a $315 million market cap is attractive as a potential investment for larger long-term gains.
How Should Investors Trade FURX Now? Find Out Here
RadioShack Corp. (NYSE:RSH), the electronics retailer seeking a new chief executive officer, climbed the most in more than five years. RadioShack advanced 22 percent to $3.22 at the close in New York, the biggest gain since July 7, 2006. The shares gained 14 percent Jan. 25. RadioShack tumbled 78 percent last year as the company posted three straight quarterly losses and suspended its dividend. The company has been seeking a new chief executive officer since September, when James Gooch stepped down and Chief Financial Officer Dorvin Lively took on the additional duties of interim CEO. Bruce Bishop, a spokesman for the Fort Worth, Texas-based company, didn’t immediately return a telephone message and e- mail seeking comment.
How Should Investors React To RSH Now? Find Out Here
Glu Mobile (NASDAQ:GLUU) has just announced that a sequel to their rather popular top-down arcade shooter Gun Bros will be arriving soon on Google Play. Appropriately named Gun Bros 2, Glu Mobile has decided to announce this sequel by releasing a cinematic trailer for this upcoming game. While the trailer doesn't show any of the gameplay that will be arriving when Gun Bros 2 is released, it does go over some of the characters and future enemies that you'll be shooting in the face relentlessly with a plethora of weapons. Unfortunately we don't have any other details about Gun Bros 2 just yet but Glu Mobile is planning on releasing additional details in the coming weeks. We are pretty sure though that it will come with multiplayer at launch this time. When they do we will be sure to post an update.
Can GVP Continue To Rise? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)